MX350009B - Derivados de 2-metoxi-piridin-4-ilo. - Google Patents

Derivados de 2-metoxi-piridin-4-ilo.

Info

Publication number
MX350009B
MX350009B MX2013007726A MX2013007726A MX350009B MX 350009 B MX350009 B MX 350009B MX 2013007726 A MX2013007726 A MX 2013007726A MX 2013007726 A MX2013007726 A MX 2013007726A MX 350009 B MX350009 B MX 350009B
Authority
MX
Mexico
Prior art keywords
derivatives
pyridin
methoxy
formula
preparation
Prior art date
Application number
MX2013007726A
Other languages
English (en)
Other versions
MX2013007726A (es
Inventor
Bolli Martin
Lescop Cyrille
Mathys Boris
Morrison Keith
Mueller Claus
Nayler Oliver
Steiner Beat
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45607310&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX350009(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2013007726A publication Critical patent/MX2013007726A/es
Publication of MX350009B publication Critical patent/MX350009B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La invención se refiere a derivados de la piridina de la Fórmula (I) (Ver Formula) Fórmula (I) donde A, R1, R2, R3 y R4 son tal como se describen en la descripción, su preparación y su empleo como compuestos farmacéuticamente activos. Dichos compuestos actúan particularmente como agentes inmunomoduladores.
MX2013007726A 2011-01-19 2012-01-18 Derivados de 2-metoxi-piridin-4-ilo. MX350009B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011050241 2011-01-19
PCT/IB2012/050241 WO2012098505A1 (en) 2011-01-19 2012-01-18 2-methoxy-pyridin-4-yl derivatives

Publications (2)

Publication Number Publication Date
MX2013007726A MX2013007726A (es) 2013-08-09
MX350009B true MX350009B (es) 2017-08-23

Family

ID=45607310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007726A MX350009B (es) 2011-01-19 2012-01-18 Derivados de 2-metoxi-piridin-4-ilo.

Country Status (28)

Country Link
US (1) US9133179B2 (es)
EP (1) EP2665720B1 (es)
JP (1) JP5859570B2 (es)
KR (1) KR101869120B1 (es)
CN (1) CN103313981B (es)
AR (1) AR084883A1 (es)
AU (1) AU2012208325B2 (es)
BR (1) BR112013017923B1 (es)
CA (1) CA2818470C (es)
CL (1) CL2013002056A1 (es)
CY (1) CY1116657T1 (es)
DK (1) DK2665720T3 (es)
ES (1) ES2544086T3 (es)
HK (1) HK1191645A1 (es)
HR (1) HRP20150919T1 (es)
HU (1) HUE026012T2 (es)
IL (1) IL227509A0 (es)
MA (1) MA34910B1 (es)
MX (1) MX350009B (es)
MY (1) MY163185A (es)
PL (1) PL2665720T3 (es)
PT (1) PT2665720E (es)
SG (1) SG191742A1 (es)
SI (1) SI2665720T1 (es)
TW (1) TWI546300B (es)
UA (1) UA109804C2 (es)
WO (1) WO2012098505A1 (es)
ZA (1) ZA201306193B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2970236T3 (en) 2013-03-15 2017-10-16 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives
JP6294872B2 (ja) 2013-04-26 2018-03-14 国立大学法人京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
CN105760707B (zh) * 2014-12-18 2018-07-31 中国科学院大连化学物理研究所 细胞基因翻译过程建模方法
EA035133B1 (ru) * 2015-05-20 2020-04-30 Идорсия Фармасьютиклз Лтд Кристаллическая форма соединения (s)-3-{4-[5-(2-циклопентил-6-метоксипиридин-4-ил)-[1,2,4]оксадиазол-3-ил]-2-этил-6-метилфенокси}пропан-1,2-диола
CN107382965A (zh) * 2017-08-14 2017-11-24 河南科技大学第附属医院 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31990A (en) 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
ZA917371B (en) 1990-09-20 1992-06-24 Merrell Dow Pharma Calcium uptake inhibitors
DE4429465A1 (de) 1994-08-19 1996-02-22 Bayer Ag Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
WO1999046277A1 (en) 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
BR0013427A (pt) 1999-08-19 2002-07-30 Nps Pharma Inc Compostos heteropolicìclicos e seus usos como antagonistas no receptor de glutamato metabotrópico
UA74419C2 (uk) 2001-02-21 2005-12-15 Ен Пі Ес Фармасьютікалс, Інк. Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
EP1625123A4 (en) * 2003-05-15 2007-08-29 Merck & Co Inc 3- (2-AMINO-1-AZACYCLYL) -5-ARYL-1,2,4-OXADIAZOLE AS S1P RECEPTOR AGONISTS
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
AU2004277947A1 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
KR20070045153A (ko) 2004-05-29 2007-05-02 7티엠 파마 에이/에스 의약용 씨알티에이치2 수용체 리간드
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
CA2583681A1 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
ES2378776T3 (es) 2004-12-13 2012-04-17 Ono Pharmaceutical Co., Ltd. Derivado de ácido aminocarboxílico y uso medicinal del mismo
EP1863475B1 (en) 2005-03-23 2011-09-07 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
ES2365747T3 (es) 2005-03-23 2011-10-10 Actelion Pharmaceuticals Ltd. Derivados de benzo[c]tiofeno hidrogenados como inmunomoduladores.
US7605269B2 (en) 2005-03-23 2009-10-20 Actelion Pharmaceuticals Ltd. Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists
US20070021443A1 (en) 2005-04-05 2007-01-25 Ohlmeyer Michael J Purine and imidazopyridine derivatives for immunosuppression
DE602006015297D1 (de) 2005-04-22 2010-08-19 Daiichi Sankyo Co Ltd 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva
KR20080000622A (ko) 2005-04-26 2008-01-02 뉴로서치 에이/에스 신규한 옥사디아졸 유도체 및 이의 의학적 용도
WO2006131336A1 (en) 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
WO2006135694A2 (en) 2005-06-10 2006-12-21 Acadia Pharmaceuticals Inc. Uii-modulating compounds and their use
AU2006260573A1 (en) 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
US20090054491A1 (en) 2005-06-28 2009-02-26 Astrazeneca Ab Use
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
WO2007086001A2 (en) 2006-01-24 2007-08-02 Actelion Pharmaceuticals Ltd Novel pyridine derivatives
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
AU2007217006A1 (en) 2006-02-21 2007-08-30 University Of Virginia Patent Foundation Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as SIP receptor agonists
WO2007132307A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
ES2400533T3 (es) 2006-09-07 2013-04-10 Actelion Pharmaceuticals Ltd. Derivados de piridin 4-ilo como agentes inmunomoduladores
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
RU2454413C2 (ru) 2006-09-08 2012-06-27 Актелион Фармасьютиклз Лтд Производные пиридин-3-ила в качестве иммуномодулирующих агентов
US8044076B2 (en) 2006-09-21 2011-10-25 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
EP2081916A1 (en) 2006-09-29 2009-07-29 Novartis AG Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties
JP2008120794A (ja) 2006-10-16 2008-05-29 Daiichi Sankyo Co Ltd ヘテロ環化合物を含有する医薬組成物
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
US7834039B2 (en) 2006-12-15 2010-11-16 Abbott Laboratories Oxadiazole compounds
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
SI2125797T1 (sl) 2007-03-16 2014-03-31 Actelion Pharmaceuticals Ltd. Derivati amino-piridina kot agonisti receptorja s1p1/edg1
CA2695509A1 (en) 2007-08-17 2009-02-26 Actelion Pharmaceuticals Ltd Pyridine derivatives as s1p1/edg1 receptor modulators
EP2193126B1 (en) 2007-10-04 2015-06-24 Merck Serono S.A. Oxadiazole diaryl compounds
KR20100075608A (ko) 2007-10-04 2010-07-02 메르크 세로노 에스. 에이. 옥사다이졸 유도체
ES2449749T3 (es) 2007-11-01 2014-03-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirimidina
EP2209771A1 (en) 2007-11-08 2010-07-28 Pfizer, Inc. Cyclobutyl carboxylic acid derivatives
KR20100095593A (ko) 2007-12-10 2010-08-31 액테리온 파마슈티칼 리미티드 Ｓ１ｐ１/ｅｄｇ１의 작동약으로서 티오펜 유도체
AU2008338965A1 (en) * 2007-12-18 2009-06-25 Arena Pharmaceuticals, Inc. Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US20110046170A1 (en) 2008-03-06 2011-02-24 Martin Bolli Novel pyrimidine-pyridine derivatives
US20110028448A1 (en) 2008-03-06 2011-02-03 Martin Bolli Pyridine compounds
WO2009109904A1 (en) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
AU2009220861B2 (en) 2008-03-07 2014-05-29 Idorsia Pharmaceuticals Ltd Pyridin-2-YL derivatives as immunomodulating agents
FI2291080T5 (fi) 2008-05-14 2023-11-06 The Scripps Research Institute Uusia sfingosiinifosfaattireseptorimodulaattoreita
US20120101134A1 (en) 2009-06-26 2012-04-26 Glaxo Group Limited 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
BR112012000763B8 (pt) 2009-07-16 2021-05-25 Actelion Pharmaceuticals Ltd compostos derivados de piridin-4-il, composição farmacêutica, e, usos de um composto

Also Published As

Publication number Publication date
PT2665720E (pt) 2015-09-16
US9133179B2 (en) 2015-09-15
HRP20150919T1 (hr) 2015-09-25
PL2665720T3 (pl) 2015-11-30
CA2818470C (en) 2019-03-05
BR112013017923B1 (pt) 2021-08-10
MA34910B1 (fr) 2014-02-01
JP2014502994A (ja) 2014-02-06
EP2665720A1 (en) 2013-11-27
ES2544086T3 (es) 2015-08-27
CY1116657T1 (el) 2018-04-04
AU2012208325A1 (en) 2013-09-05
KR101869120B1 (ko) 2018-06-19
HUE026012T2 (en) 2016-05-30
IL227509A0 (en) 2013-09-30
US20130303514A1 (en) 2013-11-14
TWI546300B (zh) 2016-08-21
CN103313981A (zh) 2013-09-18
SI2665720T1 (sl) 2015-08-31
EP2665720B1 (en) 2015-06-10
TW201309681A (zh) 2013-03-01
CA2818470A1 (en) 2012-07-26
RU2013138285A (ru) 2015-02-27
HK1191645A1 (en) 2014-08-01
BR112013017923A8 (pt) 2017-12-26
AR084883A1 (es) 2013-07-10
JP5859570B2 (ja) 2016-02-10
BR112013017923A2 (pt) 2017-03-21
AU2012208325B2 (en) 2016-12-22
MX2013007726A (es) 2013-08-09
ZA201306193B (en) 2016-07-27
KR20140014128A (ko) 2014-02-05
SG191742A1 (en) 2013-08-30
CN103313981B (zh) 2016-05-11
WO2012098505A1 (en) 2012-07-26
NZ614367A (en) 2015-02-27
UA109804C2 (xx) 2015-10-12
CL2013002056A1 (es) 2013-12-27
DK2665720T3 (en) 2015-07-13
MY163185A (en) 2017-08-15

Similar Documents

Publication Publication Date Title
MY153617A (en) Pyridin-4-yl derivatives
PH12015501412A1 (en) SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
MX2015015412A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
PH12015501083A1 (en) Novel pyridine derivatives
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
MY150661A (en) Pyridin-3-yl derivatives as immunomodulating agents
PH12015502118A1 (en) Pyridin-4-yl derivatives
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
MX346248B (es) Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2.
TW200942524A (en) Novel aminomethyl benzene derivatives
TW200942530A (en) Pyridine compounds
PH12014501415A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
MX349373B (es) Nuevos derivados de pirazina.
PH12015502409B1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
MX340574B (es) Imidazo pirazinas.
WO2014062838A3 (en) Pkm2 modulators and methods for their use
MY163185A (en) 2-methoxy-pyridin-4-yl derivatives
IN2014DN10669A (es)
JO3192B1 (ar) مركب بنزوثيازولون
PH12015500399A1 (en) Azaindolines
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
MX345264B (es) Derivado de azol.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: IDORSIA PHARMACEUTICALS LTD